Artículos de revista DE - ES Aldizkari artikuluak

Permanent URI for this collection

http://hdl.handle.net/2454/10470

Browse

Browsing Artículos de revista DE - ES Aldizkari artikuluak by Department/Institute "Osasun Zientziak"

Now showing 1 - 2 of 2
  • Thumbnail Image
    PublicationOpen Access
    Cost-utility analysis of prostatic artery embolization for treatment of lower urinary tract symptoms
    (2023) Capdevila, Ferran; Insausti, Íñigo; San Miguel Elcano, Ramón; Sánchez Iriso, Eduardo; Montesino San Martín, Manuel; Ciencias de la Salud; Osasun Zientziak; Economía; Ekonomia
    Purpose: To perform a post hoc cost–utility analysis of a randomized controlled clinical trial comparing prostatic artery embolization (PAE) and transurethral resection of the prostate (TURP) in patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. Materials and Methods: We conducted a cost–utility analysis over a 5-year period to compare PAE versus TURP from a Spanish National Health System perspective. Data were collected from a randomized clinical trial performed at a single institution. Effectiveness was measured as quality-adjusted life years (QALYs), and an incremental cost-effectiveness ratio (ICER) was derived from the cost and QALY values associated with these treatments. Further sensitivity analysis was performed to account for the impact of reintervention on the cost-effectiveness of both procedures. Results: At the 1-year follow-up, PAE resulted in mean cost per patient of €2904.68 and outcome of 0.975 QALYs per treatment. In comparison, TURP had cost €3846.72 per patient and its outcome was 0.953 QALYs per treatment. At 5 years, the cost for PAE and TURP were €4117.13 and €4297.58, and the mean QALY outcome was 4.572 and 4.487, respectively. Analysis revealed an ICER of €2121.15 saved per QALY gained when comparing PAE to TURP at long-term follow-up. Reintervention rate for PAE and TURP was 12% and 0%, respectively. Conclusions: Compared to TURP, in short term, PAE could be considered a cost-effective strategy within the Spanish healthcare system for patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia. However, in long term, the superiority is less apparent due to higher reintervention rates.
  • Thumbnail Image
    PublicationOpen Access
    Parálisis cerebral: nuevos retos en la era de las enfermedades raras
    (Gobierno de Navarra, 2023-04-09) Aguilera Albesa, Sergio; Nova Díaz, Diana Marcela; Aznal Sáinz, Elena; Economía; Ekonomia; Ciencias de la Salud; Osasun Zientziak
    Artículo editorial, que enuncia la importancia del proyecto EPCINA (Estudios de Parálisis Cerebral en Navarra: Evaluación económica, estudio de coste de la enfermedad), el cual se realiza entre el grupo de economía de la salud y el Hospital Universitaria de Navarra.